

## Drug cos face ANDA blues

“Longer waiting time for ANDA approval has impacted growth for some Indian companies given lack of new product launches,” JP Morgan analysts wrote in a note dated November 19. “This was especially aggravated in the September 2014 quarter for Indian generic players with industry witnessing price erosion from channel consolidation in the US with the upside from new launches.”

Dr Reddy's Laboratories chief operating officer Abhijit Mukherjee pointed out that decline in generic drug approvals did impact its sales to some extent in the quarter ended September 30. He said that the company is cautiously optimistic for the next quarter but the slowness in approval is witnessed throughout the sector.

Glenmark Pharmaceuticals president of North America business also mentioned during the second quarter analyst conference call that there has been a backlog in generic drug applications in the US.

RRR